Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)

ConditionAlcoholic Hepatitis

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-75

SponsorBioaraba Health Research Institute

About this trial

This study is designed to evaluate the hypothesis that patients with severe acute alcoholic hepatitis have lower morbi-mortality if the patients receive treatment with corticosteroids + NAC, compared to patients that only receive corticosteroids.

Eligibility criteria

Qualifiers

Men and women.

Age from 18 to 75 years.

Patients with acute alcoholic hepatitis according to AASLD criteria or compatible liver histology.

Maddrey score> = 32.

Disqualifiers

Any cause of jaundice: acute hepatitis, positive HIV serology, biliary-pancreatic pathology, hemolytic anemia.

Allergy or intolerance to N-acetylcysteine and / or corticosteroids.

Hepatocarcinoma.

Portal cavernomatosis.

Trial design

Treatments tested in this trial

N-acetylcysteine

Treatment groups

390 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Bioaraba Health Research Institute

Lead sponsor

Source ClinicalTrials.gov